Adaptimmune Therapeutics plc (ADAP): Price and Financial Metrics


Adaptimmune Therapeutics plc (ADAP): $1.57

0.15 (+10.56%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ADAP to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ADAP POWR Grades


  • ADAP scores best on the Value dimension, with a Value rank ahead of 84.53% of US stocks.
  • The strongest trend for ADAP is in Stability, which has been heading up over the past 179 days.
  • ADAP ranks lowest in Momentum; there it ranks in the 4th percentile.

ADAP Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for ADAP is 0.03 -- better than merely 8.5% of US stocks.
  • ADAP's price/sales ratio is 54.22; that's higher than the P/S ratio of 96.31% of US stocks.
  • In terms of volatility of its share price, ADAP is more volatile than 84.34% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Adaptimmune Therapeutics PLC, a group of peers worth examining would be DCPH, BCDA, MIST, YMAB, and MIRM.
  • ADAP's SEC filings can be seen here. And to visit Adaptimmune Therapeutics PLC's official web site, go to www.adaptimmune.com.

ADAP Valuation Summary

  • In comparison to the median Healthcare stock, ADAP's EV/EBIT ratio is 117.75% lower, now standing at -5.2.
  • ADAP's price/earnings ratio has moved up 5 over the prior 66 months.
  • Over the past 66 months, ADAP's price/sales ratio has gone up 90.5.

Below are key valuation metrics over time for ADAP.

Stock Date P/S P/B P/E EV/EBIT
ADAP 2021-08-31 129.7 2.9 -5.4 -5.2
ADAP 2021-08-30 131.4 2.9 -5.5 -5.3
ADAP 2021-08-27 129.2 2.9 -5.4 -5.2
ADAP 2021-08-26 126.7 2.8 -5.3 -5.1
ADAP 2021-08-25 124.2 2.8 -5.2 -5.0
ADAP 2021-08-24 109.9 2.5 -4.6 -4.4

ADAP's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ADAP has a Quality Grade of C, ranking ahead of 58.13% of graded US stocks.
  • ADAP's asset turnover comes in at 0.016 -- ranking 378th of 682 Pharmaceutical Products stocks.
  • CALA, ACOR, and INSM are the stocks whose asset turnover ratios are most correlated with ADAP.

The table below shows ADAP's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.016 1 -0.462
2021-06-30 0.014 1 -0.414
2021-03-31 0.008 1 -0.374
2020-12-31 0.009 1 -0.397
2020-09-30 0.009 1 -0.466
2020-06-30 0.008 1 -0.617

ADAP Stock Price Chart Interactive Chart >

Price chart for ADAP

ADAP Price/Volume Stats

Current price $1.57 52-week high $6.86
Prev. close $1.42 52-week low $1.26
Day low $1.46 Volume 377,100
Day high $1.61 Avg. volume 889,601
50-day MA $1.90 Dividend yield N/A
200-day MA $3.60 Market Cap 254.13M

Adaptimmune Therapeutics plc (ADAP) Company Bio


Adaptimmune Therapeutics plc is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor platform. The company was founded in 2014 and is based in Abingdon, the United Kingdom.


ADAP Latest News Stream


Event/Time News Detail
Loading, please wait...

ADAP Latest Social Stream


Loading social stream, please wait...

View Full ADAP Social Stream

Latest ADAP News From Around the Web

Below are the latest news stories about Adaptimmune Therapeutics PLC that investors may wish to consider to help them evaluate ADAP as an investment opportunity.

Clovis (CLVS) Q4 Loss Narrower than Expected, Revenues Lag

Clovis (CLVS) reports narrower-than-expected loss for fourth-quarter 2021. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts.

Yahoo | February 24, 2022

Agios (AGIO) Gets FDA Nod for Rare Anemia Drug Mitapivat

Agios Pharmaceuticals' (AGIO) Pyrukynd (mitapivat) is the first disease-modifying therapy approved to treat PK deficiency, a rare, debilitating, blood disorder.

Yahoo | February 18, 2022

Repligen (RGEN) Q4 Earnings and Revenues Surpass Estimates

Repligen's (RGEN) fourth-quarter earnings and revenues beat estimates. It expects to achieve revenue growth in the range of 19-24% in 2022.

Yahoo | February 18, 2022

CRISPR Therapeutics (CRSP) Q4 Earnings Miss, Revenues Up Y/Y

CRISPR Therapeutics (CRSP) reports wider-than-expected Q4 loss. Nonetheless, revenues beat estimates.

Yahoo | February 16, 2022

Zoetis' (ZTS) Q4 Earnings and Revenues Surpass Estimates

Zoetis' (ZTS) earnings and revenues beat estimates for the fourth quarter of 2021.

Yahoo | February 15, 2022

Read More 'ADAP' Stories Here

ADAP Price Returns

1-mo -14.67%
3-mo -47.67%
6-mo -63.06%
1-year -69.34%
3-year -57.22%
5-year -70.87%
YTD -58.13%
2021 -30.43%
2020 349.17%
2019 -79.13%
2018 -13.92%
2017 64.94%

Continue Researching ADAP

Here are a few links from around the web to help you further your research on Adaptimmune Therapeutics PLC's stock as an investment opportunity:

Adaptimmune Therapeutics PLC (ADAP) Stock Price | Nasdaq
Adaptimmune Therapeutics PLC (ADAP) Stock Quote, History and News - Yahoo Finance
Adaptimmune Therapeutics PLC (ADAP) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8916 seconds.